Rheumatoid Arthritis

The Pharmacy Times® Rheumatoid Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?

FDA Approves Golimumab for Active Polyarticular Juvenile Idiopathic Arthritis, Extension of PsA Indication

The FDA has approved golimumab for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

Study: Rheumatoid Arthritis Associated with Increased Type 2 Diabetes Risk

Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.

Tofacitinib Approved for Polyarticular Juvenile Idiopathic Arthritis

The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.

Study: Certain Immunosuppressing Drugs Do Not Increase Risk for Contracting COVID-19

A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.

COVID-19 Studies Show Impact to Certain Patients With Autoimmune Conditions

Recent studies have analyzed how individuals with autoimmune conditions prescribed specialty medications may be affected by the COVID-19 pandemic.

Study: Mediterranean Diet May Protect Against Rheumatoid Arthritis

The Mediterranean diet has shown efficacy in preventing several noncommunicable diseases.

Research Shows Adults With Lupus, Common Types of Arthritis Have Similar Risks of Being Hospitalized as Other Patients With COVID-19

The new studies found that for some patients, the use of steroid medications to reduce inflammation slighly increased the likelihood of needing hospital care for COVID-19.

Study: Long-Term Glucocorticoid Use May Lead to Severe Adverse Events

Extended glucocorticoid use can cause complications such as cardiovascular disorders, infections, and osteoporosis, according to a new study.

Treating COVID-19 or Rheumatoid Arthritis? Exploring Proposed Drug Therapy, Safety Concerns

What characteristics of RA treatments possibly connect to COVID-19 treatment?

American College of Rheumatology Releases Position Statement on Prior Authorization

The American College of Rheumatology addresses the prior authorization requirement for some prescription medications, highlighting the significant burden this creates for patients and rheumatology professionals.

Class of Cancer Drugs May Have Potential as Chronic Obstructive Pulmonary Disease Treatment

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

FDA Approves Infliximab-Axxq as Biosimilar to Infliximab

Officials with the FDA have approved Amgen’s infliximab-axxq (Avsola), a new biosimiliar to infliximab (Remicade).

The Pharmacy Times® Oncology resource center provides a home for all of the latest clinical information that both oncologists and pharmacists that work within the field could find valuable. With articles covering updates from the robust pipeline of novel neurological therapies, and the newest data from all phases of clinical trials and studies in the space, it also serves as a hub of coverage from ongoing conferences and annual meetings of oncological associations, like ASCO, the American Society of Clinical Oncology.